NexaGen Pharmaceuticals is facing an unprecedented crisis following a Thursday break-in at their Metro City research campus that resulted in both a massive data breach and the theft of controlled chemical compounds.
The incident, which occurred between approximately 1:00 AM and 4:30 AM on May 8-9, shares characteristics with previous security breaches attributed to the unidentified individual known as TerrorByte. Metro City Police have confirmed the FBI's joint task force is involved in the investigation.
The Break-In
According to the Metro City Police Department, an unknown individual gained access to two buildings on NexaGen's Innovation Drive campus without triggering alarms or leaving evidence of forced entry. Security cameras recorded no anomalies. Access logs show no unauthorized entries.
Six security personnel were confined to a break room for approximately three hours when the building's keycard system experienced simultaneous failures. All six were unharmed.
A single witness, identified as Dr. Sarah Chen, a NexaGen researcher, observed a figure crossing the campus courtyard at approximately 4:15 AM. Dr. Chen described the individual as "average height, wearing dark clothing." Campus lighting malfunctions and distance prevented a more detailed description.
The Data Leak
Beginning at approximately 3:47 AM, multiple news organizations, medical journals, and federal agencies received encrypted file transfers containing what appear to be internal NexaGen documents. The documents allege:
- Clinical trial results for Serenix were falsified to underreport addiction rates (alleged 23% actual vs. 4% reported)
- 847 adverse event reports were allegedly deleted before FDA submission
- Three FDA reviewers allegedly received payments totaling $2.3 million
- Internal emails allegedly show executives were aware of elevated addiction risks and mortality rates
NexaGen has not confirmed or denied the authenticity of the documents. CEO Richard Holt and Chief Science Officer Amanda Cross resigned within 24 hours of the leak.
The Chemical Theft
According to sources familiar with the investigation, the following materials were reported missing from NexaGen's laboratories:
- 12 liters of "Compound NX-7" (described as a synthetic precursor)
- 3 kilograms of refined cathinone derivatives (a controlled substance category)
- 800 milliliters of an experimental nootropic compound
The Drug Enforcement Administration has been notified of the controlled substance theft. NexaGen has declined to provide details about the properties or potential applications of the stolen compounds.
Serenix: The Drug in Question
Serenix received FDA approval in 2042 and has since become one of the most widely prescribed anti-anxiety medications in the United States. NexaGen reported approximately 40 million prescriptions written since its launch.
According to the leaked documents, if authenticated, NexaGen's internal data showed significantly higher addiction rates than publicly disclosed. The documents also allege that approximately 2,300 deaths have been linked to Serenix withdrawal complications over the past three years.
Timeline of Events
- 2042: Serenix receives FDA approval
- 2044: Independent study raises addiction concerns
- May 8, 2045, ~1:00 AM: Break-in begins
- May 8, 2045, ~3:47 AM: Data transfers initiated
- May 8, 2045, ~4:15 AM: Witness observes figure on campus
- May 9, 2045, 6:45 AM: Break-in discovered and reported
- May 9, 2045: CEO and CSO resign
- May 10, 2045: Class action lawsuits filed; FDA investigation announced
This story will be updated as information becomes available.